Articles related to BUSINESS & POLICY

Examine how programs like Hospital at Home are changing the face of healthcare, providing acute treatment outside of hospitals, enhancing patient outcomes, and ushering in a new era of patient-centered care.

Unpacking the landmark summit led by the American Pharmacists Association, it becomes clear that there is a pressing need and opportunity to expand healthcare coverage for pharmacists’ patient care services, promising substantial impacts on patient care and health systems.

It’s clear that addressing the carbon footprint in intensive care units (ICUs) is an important area of concern in tackling the climate crisis. As ICUs are a carbon hotspot, various measures can be taken to reduce their impact on the environment without compromising patient care.

Treading the line between cost-effectiveness and equity in SCD management, gene therapy presents a paradigm shift. Curious about the economic equilibrium in this new era of treatment? Dive into the latest research insights.

Addressing the Crisis: Reinventing the Clinical Research Workforce The clinical research enterprise, the backbone of medical advancement, is at a crossroads. A deep-seated crisis in the workforce threatens to halt progress, demanding urgent, systemic solutions. Key Points: “Now is the time to fix the evidence generation system.” US Food and Drug Administration (FDA) Commissioner Robert M. Califf in January 2023

Join us as we explore the dynamic world of compounding pharmacies tackling the challenging semaglutide shortages head-on. Compounding pharmacies have stepped up to address the shortage of two semaglutide products, Ozempic and Wegovy. Consequently, they’re facing increased scrutiny from federal and state regulators, as well as Novo Nordisk, the manufacturer of these products. Novo Nordisk is actively monitoring and taking action against entities unlawfully selling compounded semaglutide. The company has sent cease-and-desist letters to some 503A pharmacy compounders. This move is seen as the first step towards potential legal actions. The Alliance for Pharmacy Compounding has defended the rights of 503A pharmacies to compound active pharmaceutical ingredients (APIs) in brand-name medications for specific patients, as long as the brands are on the FDA’s “currently in shortage” list. However, the distinction between legitimate 503A pharmacy compounders and shady operators has been blurred. These operators have rushed to fill the semaglutide gap without proper oversight of their compounding safety processes, source of APIs, or marketing techniques. This negligence could potentially cause serious patient harm. Kristina Bryowsky, PharmD, MBA, Vice President of Pharmacy Services for SSM Health Care, Missouri Region, believes that 503A compounding pharmacies should be allowed to make a product for […]